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Abstract
Organic acidurias (OADs) comprise a biochemically defined group of inherited
metabolic diseases. Increasing awareness, reliable diagnostic work-up, newborn
screening programs for some OADs, optimized neonatal and intensive care, and
the development of evidence-based recommendations have improved neonatal
survival and short-term outcome of affected individuals. However, chronic pro-
gression of organ dysfunction in an aging patient population cannot be reliably
prevented with traditional therapeutic measures. Evidence is increasing that dis-
ease progression might be best explained by mitochondrial dysfunction. Previous
studies have demonstrated that some toxic metabolites target mitochondrial pro-
teins inducing synergistic bioenergetic impairment. Although these potentially
reversible mechanisms help to understand the development of acute metabolic
decompensations during catabolic state, they currently cannot completely
explain disease progression with age. Recent studies identified unbalanced
autophagy as a novel mechanism in the renal pathology of methylmalonic
aciduria, resulting in impaired quality control of organelles, mitochondrial aging
and, subsequently, progressive organ dysfunction. In addition, the discovery of
post-translational short-chain lysine acylation of histones and mitochondrial
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enzymes helps to understand how intracellular key metabolites modulate gene
expression and enzyme function. While acylation is considered an important
mechanism for metabolic adaptation, the chronic accumulation of potential sub-
strates of short-chain lysine acylation in inherited metabolic diseases might exert
the opposite effect, in the long run. Recently, changed glutarylation patterns of
mitochondrial proteins have been demonstrated in glutaric aciduria type 1. These
new insights might bridge the gap between natural history and pathophysiology
in OADs, and their exploitation for the development of targeted therapies seems
promising.
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1 | OLD ROADS, MAJOR GAPS
Organic acidurias or acidemias (OADs) are a group of
inherited metabolic diseases, which has been identified
following the introduction of analytical gas chromatogra-
phy techniques since the 1960s. The name-giving
biochemical hallmark of OADs is the accumulation of
so-called “organic acids,” that is, nonamino mono-, di- or
tricarboxylic acids which can be detected in urine,
plasma, and cerebrospinal fluid. In the majority of OADs,
this is caused by deficient mitochondrial breakdown of
CoA-activated carbonic acids such as propionyl-CoA,
methylmalonyl-CoA, isovaleryl-CoA, and glutaryl-CoA.
Some of these are thought to be toxic, mostly through
induction of mitochondrial dysfunction, energy impair-
ment, and oxidative stress, resulting in acute and chronic
dysfunction of organs with a high energy demand1-10
(Figure 1). Systematic data analysis of 181 publications
on individuals with isolated methylmalonic (MMA;
OMIM #25100) and propionic aciduria (PA; OMIM
#606054) has recently supported the previous notion of
mitochondrial impairment playing a major role in these
diseases,11 particularly in the manifestation of cardiomy-
opathy, optic atrophy, abnormalities of basal ganglia and
the liver, pancreatitis, and epilepsy.11,12
Observational studies, demonstrating overlapping clin-
ical phenotypes between OADs and phenotypic diversity
in individuals with the same OAD, even in siblings,13,14
have significantly changed our view on the long-term out-
come of affected individuals. First, the traditional division
in “classic” and “cerebral” OADs has been challenged,
since the brain is most often involved in both subgroups,
while cerebral OADs may also develop non-neurologic
disease manifestations such as chronic kidney disease
(CKD) in glutaric aciduria type 115 (GA1; OMIM #231670)
and cardiomyopathy in D-2-hydroxyglutaric aciduria type
2 (OMIM #613657).16 Second, CKD, originally assigned to
MMA (OMIM #251110),17 is also found in PA patients,
however, at a later age than in MMA patients.13,18 Finally,
these studies have challenged our view about the disease
onset. Because of the tight metabolic coupling between a
mother and her unborn child, a fetus having an OAD is
commonly thought to be protected during pregnancy. This
notion is supported by the fact that individuals with
potentially life-threatening OADs are usually born asymp-
tomatically and start to present first symptoms after a vari-
able postnatal time interval. However, the observation of
macrocephaly, hypoplasia of the temporal lobe, and
immature gyral pattern of the cortex in newborns with
GA1, and of low birth weight in mut0-type MMA
highlights that the maternal metabolism may not
completely prevent disease manifestation in utero and
that other mechanisms on a subcellular level might fuel
organ-specific disease manifestations.13,19
With improved survival and longer follow-up, knowl-
edge about OADs is increasing, unraveling major gaps and
new challenges. Most strikingly, early diagnosis and adher-
ence to recommended conservative metabolic management
using combinations of dietary treatment, cofactors,
carnitine supplementation, nonabsorbable antibiotics, and
intensified emergency management during catabolic
episodes cannot reliably prevent disease progression, which
does not even spare those who have not had a single acute
metabolic decompensation for years (if ever).20-25
Furthermore, a growing number of individuals with OADs
are found to develop cerebral neoplasms such as in
L-2-hydroxyglutaric aciduria (OMIM #236792) and
GA1,26,27 and hepatic neoplasms like in MMA.28,29 Lastly,
although plasma ammonium, acid-base balance, and anion
gap are useful to estimate the risk of a metabolic decom-
pensation in a “classic” OAD patient and to guide
therapeutic decision-making,30,31 these basic biomarkers as
well as disease-specific carbonic acids and acylcarnitines
have a low predictive value for the long-term outcome.20
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The same holds true for the genotype, except in cofactor-
sensitive OADs. Therefore, the term “metabolic stability”
seems poorly defined for the group of OADs and even
misleading.
These studies highlight major gaps that currently ham-
per the improvement of health outcomes in individuals
with OADs. This review aims to critically discuss current
pathogenetic concepts and to look beyond these horizons
in order to identify strategies to bridge existing gaps.
2 | FROM DEFICIENCY TO
DISEASE: ON BOTTLE NECKS,
INSURMOUNTABLE BORDERS, AND
SLOPPY ENZYMES
Inherited deficiencies of proteins involved in metabolic
pathways are various and do not necessarily result in a
clinically apparent disease. As an example, hydro-
xyprolinemia (OMIM #237000) caused by deficient
dehydrogenation of hydroxyproline to Δ1-pyrroline-
3-hydroxy-5-carboxylic acid due to biallelic mutations in
PRODH2 is thought to be a benign condition.32 It is a fre-
quent cause of false positive newborn screening for
maple syrup urine disease (OMIM #248600).
The group of OADs is an interesting example to study
the necessary preconditions of the transfer from an
inherited protein dysfunction to a disease. The formation
of toxic metabolites is thought to play a pivotal role for
OADs. But what makes a metabolite toxic? First, this
metabolite should accumulate to exceed a certain thresh-
old that is required to drive the adverse action. Accord-
ingly, one or more of the following criteria should be
met: (a) The metabolic block cannot be bypassed and
thus compensated by an isoenzyme or another metabolic
pathway acting in parallel to the deficient pathway. For
FIGURE 1 Synergistic pathways to mitochondrial toxicity in organic acidurias. Accumulating CoA esters and carbonic acid such as
propionyl-CoA (Prop-CoA), 2-methylcitrate (MCA), methylmalonate (MMA) in propionic and/or methylmalonic aciduria as well as glutaryl-
CoA (Glut-CoA), glutarate (GA), and 3-hydroxyglutarate (3OHGA) in GA1 inhibit key enzymes of energy metabolism, with a particular focus
on the tricarboxylic acid cycle (TCA). Besides metabolite-induced inhibition of key enzymes, the TCA cycle flux is further impaired by
physiologic, inherited or acquired deficiency of anaplerotic pathways such as pyruvate carboxylase (in neurons), propionate oxidation (in PA
and MMA), and glutamate dehydrogenase (GDH, in GA1), metabolite-induced inhibition of sodium-dependent dicarboxylic acid transporter
3 (NC3; in GA 1), and cataplerosis due to 2-oxoglutarate-dependent synthesis of L-2-(L2OHGA) and D-2-hydroxyglutarate (D2OHGA). Overall,
the mitochondrial metabolism is compromised by CoA sequestration and limited availability of free CoA. ACO2, aconitase 2; CASTOR, CoA
sequestration, toxicity or redistribution; CS, citrate synthase; FADH2, dihydroflavine adenine dinucleotide; GTP, guanosine triphosphate; IDH,
isocitrate dehydrogenase; IDH2mut, mutated form of isocitrate dehydrogenase 2; Iso, isoleucine; MDH, malate dehydrogenase; MUT,
methylmalonyl-CoA mutase; NADH, nicotinamide adenine dinucleotide; OGDHc, 2-oxoglutarate dehydrogenase complex; OXPHOS, oxidative
phosphorylation; PC, pyruvate carboxylase; PCC, propionyl-CoA carboxylase; PDHc, pyruvate dehydrogenase complex; R-CoA, acyl-CoAs; SCS,
succinyl-CoA synthetase; Thr, threonine; Val, valine
DIMITROV ET AL. 3
example, only glutaryl-CoA dehydrogenase (GCDH; EC
1.3.8.6) is known to catalyze the oxidative decarboxyl-
ation of glutaryl-CoA to crotonyl-CoA, while the forma-
tion of glutaryl-CoA from its precursor 2-oxoadipate can
be handled by both, dehydrogenase E1 and transketolase
domain-containing protein 1 (preferring 2-oxoadipate as
a substrate; EC 1.2.4.2) and 2-oxoglutarate dehydrogenase
(OGDH, preferring 2-oxoglutarate but also accepts
2-oxoadipate as a substrate; EC 1.2.4.2).8,33 (b) Enzymatic
dysfunction gives rise to (noncanonical) metabolites that
cannot be further metabolized such as L-2-hydroxy-
glutarate34 or 3-hydroxyglutarate35 due to inherited loss
or nonexistence of a metabolite repair enzyme. (c) The
assumingly toxic metabolite cannot cross a given border,
specifically a biological membrane, and hence is
entrapped in an intracellular compartment. It is well
known that the inner mitochondrial membrane is imper-
meable to free CoA and CoA esters, requiring a carnitine-
dependent translocation to cross it.36 Although this
mechanism orchestrates mitochondrial and cytosolic
metabolism, it also facilitates the mitochondrial accumu-
lation of toxic CoA esters arising from inherited deficien-
cies of mitochondrial enzymes such as L-methylmalonyl-
CoA mutase (EC 5.4.99.2) or propionyl-CoA carboxylase
(EC 6.4.1.3). The consequences of CoA sequestration and
toxicity or redistribution have been summarized previ-
ously in the so-called CASTOR hypothesis,36 a variant
form of the toxic metabolite hypothesis.37 Another exam-
ple of a pathomechanistically relevant biological barrier
is the blood-brain barrier. In the amino acid disorders
phenylketonuria and maple syrup urine disease, the
expression of the LAT1 transporter in microvascular
endothelial cells is the prerequisite for increased trans-
port of the essential amino acids L-phenylalanine and L-
leucine, respectively, from plasma to the brain interstitial
fluid, competing with other large neutral amino acids
using the same transporter and, as consequence, causing
harm to the brain.38-40 In OADs, the lack of an effective
efflux transport for di- and tricarboxylic compounds
across the blood-brain barrier relevantly contributes to
the cerebral accumulation of neurotoxic glutarate and
3-hydroxyglutarate in GA1, 2-methylcitrate in MMA and
PA, and methylmalonate in MMA (entrapment hypothe-
sis).41,42 At supraphysiologic concentrations, glutaric acid
induces dysfunction of the blood-brain barrier, however,
with unclear pathophysiologic relevance for GA1.10,43
Besides accumulation, a second major requirement for
a toxic metabolite is the presence of one or more impor-
tant intracellular targets to harm the affected organism.
Enzymes are not absolutely substrate-specific at a low rate
and can also accept metabolites that share similarities
with their preferred substrate. An example for this
“substrate promiscuity” is L-malate dehydrogenase
(EC 1.1.1.37), performing a side activity on 2-oxoglutarate
thereby producing L-2-hydroxyglutarate. Furthermore,
enzymes can catalyze an incorrect reaction on their physi-
ological substrate (“catalytic promiscuity”),44 resulting in
side-products of canonical enzymes as well as non-
canonical metabolites. Pathomechanistic studies on OADs
have unraveled that enzymes can also become the target
of toxic metabolites that resemble physiological inhibitors,
what may be termed “inhibitor promiscuity”. For example,
it was demonstrated that glutaryl-CoA inhibits the E2 sub-
unit of the OGDH complex, resembling the feedback inhi-
bition of its physiologic product succinyl-CoA and thereby
causing dysfunction of the tricarboxylic acid (TCA) cycle
in GA1.6 In analogy, propionyl-CoA, which accumulates
in MMA and PA, resembles the feedback inhibition of
acetyl-CoA acting at the pyruvate dehydrogenase complex
(EC 1.2.4.1) and thereby disconnects anaerobic and
aerobic ATP production.45
3 | NEW CONNECTIONS: FROM
MITOCHONDRIAL DYSFUNCTION
TO IMPAIRED MITOPHAGY
Previous studies have shown that accumulating toxic acyl-
CoAs and carbonic acids affect mitochondrial energy
metabolism in a synergistic way (Figure 1). Underlying
mechanisms have been reviewed previously4,9-12 and are
therefore only briefly summarized here. In GA1, it is pos-
tulated that glutaryl-CoA inhibits the TCA cycle via the
OGDH complex,6 while glutarate and 3-hydroxyglutarate
impair the exchange of TCA cycle intermediates
between astrocytes and neurons via inhibition of
sodium-dependent dicarboxylate transporters, disrupting
their bioenergetic coupling.46,47 Furthermore, glutarate
impairs astroglial glutaminolysis, an important anaplerotic
mechanism, via inhibition of glutamate dehydrogenase
(GDH, 1.4.1.3).48 Also, energy supply of the brain could be
further impaired by 3-hydroxyglutaric acid-induced
vascular dysfunction and glutarate-mediated alteration of
capillary pericyte contractility,49,50 which may explain dis-
turbed autoregulation of cerebral blood flow.51 As a conse-
quence of mitochondrial dysfunction and excitotoxic
mechanisms the production of reactive oxygen species
(ROS) is increased.10 In MMA and PA, the primary enzy-
matic defects are located in the propionate pathway that
fuels succinyl-CoA into the TCA cycle, another important
anaplerotic mechanism. Intramitochondrially accumulat-
ing propionyl-CoA impairs energy metabolism via
inhibition of the pyruvate dehydrogenase complex45 and
succinate-CoA synthetase (EC 6.2.1.4),52 and ureagenesis
via inhibition of N-acetylglutamate synthase (EC
2.3.1.1).53 The TCA cycle flux is further disturbed by
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2-methylcitrate-mediated inhibition of the TCA enzymes
citrate synthase (EC 2.3.3.1), aconitase 2 (EC 4.2.1.3), and
isocitrate dehydrogenase (EC 1.1.1.42),54 and by
methylmalonate-induced inhibition of mitochondrial suc-
cinate uptake.55 Mitochondrial dysfunction, stress
signaling, and apoptosis were demonstrated via altered
miRNA expression in a PA mouse model,56 and oxidative
stress was shown in MMA and PA patient fibroblasts.57,58
The major strength of this concept is that it can explain
acute metabolic decompensations via synergistically acting
pathways leading to mitochondrial dysfunction. These
inhibitory mechanisms, however, are potentially reversible
with decreasing toxic metabolite concentrations. There-
fore, the weak point of this concept is the progressive
organ dysfunction in supposedly “metabolically stable”
individuals with an OAD, which might be explained by
sustained mechanisms that aggravate organ dysfunction
with age. Evidence for sustained mitochondrial pathology
was found in Gcdh−/− mice, showing enlarged mitochon-
dria with reduced electron density during induced meta-
bolic crises,59 and in HeLa cells transfected with mutant
GCDH, revealing elongation of mitochondria and dis-
turbed inner mitochondrial membrane organization.60
Progression of mitochondrial dysmorphology and dysfunc-
tion was also demonstrated in liver, kidney, skeletal and
heart muscle of MMA and PA patients, showing multiple
deficiencies of respiratory chain complexes and thus
partially resembling mitochondrial DNA depletion syn-
dromes. In analogy, reduced cytochrome c oxidase was
shown in Mut−/− mice, being accompanied by progressive
organ dysfunction and the formation of mega-
mitochondria.1,45,61,62 Chronic depletion of mitochondrial
DNA, possibly caused by propionyl-CoA induced inhibi-
tion of succinyl-CoA synthetase, was initially suggested as
putative mechanism but was not unequivocally supported
by experimental data.1,45,61
A recent publication demonstrated increased expres-
sion and activities of mitochondrial enzymes including
cytochrome c oxidase in cultivated kidney cells of mut0-
type MMA patients, which unlike control cells were
unresponsive to mitochondrial inhibitors such as rote-
none.63 In the same model, the observation of unbal-
anced autophagy opened a new perspective for
pathophysiological research in OADs, linking mitochon-
drial dysfunction to subsequent organelle aging. Electron
microscopy revealed an increased number of lamellar
bodies in mutase-deficient kidney cells as well as in
Mut−/−;TgINS-Alb-Mut mice, indicating increased produc-
tion of autophagosomes and autolysosomes and linking
ultrastructural changes in the proximal tubule mitochon-
dria to the manifestation of tubulointerstitial nephritis
and, subsequently, chronic kidney failure, which aggra-
vated the accumulation of methylmalonic acid.64
Enhanced macro-autophagy (or nonselective autophagy),
supposedly induced by mitochondria-derived ROS, was
also supported by increased levels of LC3-II and p62
under metabolic stress and was explained by reduced
expression of mTORC1.65 Similar morphologic alter-
ations were obtained in the livers of transplanted MMA
patients.5 In MMA kidney cells, altered homeostasis of
the mitochondrial network and reduced membrane
potential was found to be accompanied by oxidative
stress and increased macro-autophagy.65 Macro-
autophagy is an evolutionary conserved mechanism that
enables the degradation of cells containing dysfunctional
mitochondria and subsequent renewal through biogene-
sis.66 While macro-autophagy and autolysosomal biogen-
esis are promoted via regulation of upstream signaling
cascades in MMA, patient-derived kidney cells and pri-
mary proximal tubular cells of mmut-deleted mice fail to
clear dysfunctional mitochondria through PINK1/Parkin-
mediated mitophagy (or organelle-specific, targeted
autophagy), despite unchanged lysosomal dynamics.
Concomitantly increased macro-autophagy and disturbed
mitophagy highlight unbalanced autophagy. Mitophagy
is an important mechanism by which exhausted and
selectively targeted mitochondria are cleared. Deficiency
of the mitophagy pathway in MMA patients hence
explains CKD by accumulation of dysfunctional ROS-
producing organelles and enhanced renal epithelial stress
(Figure 2). Noteworthy, treatment with the mitochon-
dria-targeted antioxidant mito-TEMPO partially restored
mitochondrial function and mitophagy. These findings
underline the importance of the mitochondrial quality
control system and offer potentially targetable aims
which might be exploited for innovative therapies. In
conclusion, theoretically reversible mitochondrial dys-
function induced by increased toxic metabolite concen-
trations during catabolism or protein intake beyond
individual tolerance might be sustained by impairment of
an important quality control system that is required to
eliminate damaged organelles, to maintain functional
mitochondria, and to meet energy demands. It needs to
be evaluated carefully whether this mechanism also
underlies progressive dysfunction in other organs of
MMA patients and in other OADs.
4 | FROM THE MITOCHONDRIAL
CONFLUENCE OF COA ESTERS TO
POST-TRANSLATIONAL PROTEIN
ACYLATION
An increasing number of intracellular short-chain
mono- and dicarboxylic acyl-CoAs have been shown to
be involved in post-translational short-chain acylation
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of the ε-group of lysine residues in histones and
enzymes,67 regulating gene expression and enzymatic
activity and hence adapting metabolic activities to the
current demands.
In 1963, enzymatically driven histone acetylation was
the first discovered protein acylation,68,69 and further post-
translational modifications such as butyrylation, pro-
pionylation, 2-hydroxyisobutyrylation, succinylation, mal-
onylation, crotonylation, β-hydroxybutyrylation, and
glutarylation were subsequently described (Figure 3).
Short-chain acylation changes the chemical properties of
the modified amino acid residues by adding a hydrophobic,
polar, or acidic group, and hence modulates the ability to
form hydrogen bonds, electrostatic interactions with nega-
tively charged residues, and van der Waals interactions
with other proteins.67 The general amount of acyl-CoAs
can influence histone acylation and therefore affect gene
expression.70 For example, under low glucose conditions
more nonacetyl histone acylations are present, while under
high glucose conditions and concomitantly increasing
acetyl-CoA concentration histone acetylation becomes pre-
dominant.71 Changing the abundance of post-translational
modifications of histones enables an organism to adapt its
biological processes and cellular metabolism to nutrient
supply by fundamental metabolite sensing.72,73
In contrast to histone acylation, short-chain acylation
of mitochondrial proteins is enzyme-independent. In indi-
viduals with OADs, disease-specific acyl-CoAs are formed
in the mitochondria. Since the inner mitochondrial mem-
brane is impermeable to acyl-CoAs, their accumulation in
the mitochondrial compartment is facilitated, whereas a
direct impact of fluctuating acyl-CoAs on regulatory pro-
teins in the nucleus is limited.74,75 In other words, different
branches of metabolism generate specific classes of acyl-
CoAs whose regulatory impact is determined by intracellu-
lar compartments. In OADs, the variety of disease-specific
acyl-CoAs drives the diversity of acylations of metabolic
proteins, particularly in mitochondria.76-78 Under physio-
logic conditions, most adaptations are short-term and con-
stantly changing with the metabolic state. In case of OADs
like GA1, PA, and MMA, however, the permanent and
massive increase in certain mitochondrial acyl-CoAs may
result in chronically enhanced nonenzymatic, metabolite-
sensitive mitochondrial protein acylation, even during
intervals of supposedly “metabolic stability”.79,80
In line with these assumptions, Gcdh−/− mice revealed
markedly increased global protein glutarylation already
under standard conditions.81 Among them, hyperg-
lutarylated carbamylphosphate synthetase 1 (EC 6.3.4.16),
a mitochondrial enzyme involved in ureagenesis, was less
active than in wild-type mice but showed increased
enzyme expression, presumably to compensate for
reduced GCDH enzymatic activity. Further investigation
of the glutarylomes in liver and brain homogenates of
Gcdh−/− mice identified 148 and 35 glutarylated proteins,
respectively, varying in their number of glutarylation sites
FIGURE 2 Unbalanced
autophagy: impairment of
mitochondrial quality control
system. Mitochondria of MMA
patients experience functional
and morphological changes due
to the accumulation of toxic
metabolites (left). Because of a
defective mitochondrial quality
control system (controlled by its
key players PINK1/parkin)
dysfunctional mitochondria
cannot be correctly delivered to
the autophagy-lysosome system
inducing epithelial stress and
concomitant tissue damage
(middle). Macro-autophagy is
activated as a compensatory
mechanism (right)
Source: With modifications from:
Ruppert, Schumann63; Manoli5;
Luciani65
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and their role in various metabolic pathways. Ultrastruc-
tural analysis unraveled glutarylated proteins in the brain
to be exclusively localized in glial cells, with specifically
reduced catalytic activities of glutarylated GDH and brain-
specific carbonic anhydrase 5b (EC 4.2.1.1).82 The exclu-
sive astroglial localization of glutarylated proteins was
unexpected since in the brain GCDH is predominantly
expressed in neurons83 and—less pronounced—in cortical
astrocytes. Although murine Gcdh−/− astrocytes seem to
able to produce low amounts of glutaric and
3-hydroxyglutaric acid, and although astrocytic produc-
tion can be stimulated by supraphysiological concentra-
tions of lysine, it remains to be elucidated why
mitochondrial proteins in neurons escape enhanced glu-
tarylation as mitochondria of neurons are assumed to be
the major source of glutaryl-CoA in the brain.83
The net effect of glutarylated astroglial proteins is also
far from being understood. While protein glutarylation
was originally supposed to limit the astroglial synthesis of
glutamate and thus to adapt glial cells to the metabolic
demands of neighboring Gcdh−/− murine neurons, the
opposite effect seems even more likely, since GDH is an
important anaplerotic enzyme that feeds 2-oxoglutarate
in the TCA cycle. Three consequences of increased GDH
glutarylation seem possible: First, it may lead to
decreased astroglial GDH activity and, subsequently,
increased glutamate levels in the synaptic cleft. Second, it
may deplete the mitochondrial 2-oxoglutarate pool,
impairing anaplerosis and energy production, and third,
it may affect the formation of GDH- and GCDH-
containing enzymatic supercomplexes. These mecha-
nisms may further impair the astroglial provision of TCA
cycle intermediates for neurons and hence the metabolic
coupling of astrocytes and neurons,41,47 thereby promot-
ing excitotoxic mechanisms.84
It remains to be unraveled whether selective astroglial
protein glutarylation underlies white matter changes pre-
dominantly found in GA1 patients with a high excretor
phenotype, and progress with age despite adherence to
metabolic therapy.85,86
5 | THE YET UNFULFILLED
PROMISE OF SAFE AND
DISEASE-CHANGING THERAPIES
Evidence-based recommendations for the diagnosis, ther-
apy, and long-term management of individuals with GA1,
FIGURE 3 Metabolic regulation of short-chain lysine acylation. The concentrations of intracellular acyl-CoA esters such as acetyl-CoA
and short chain acyl-CoAs (R-CoA) reflect metabolic activity and the availability of energy substrates. Besides many other metabolic
functions, acyl-CoA esters can also serve as a substrate for post-translational acylation of lysine residues of histones and enzymes, changing
gene expression and enzymatic activity to adapt metabolic activity in a coordinated way by metabolite sensing. Chronic increase in R-CoA
esters, however, might result in metabolic maladaptation in the long run. ACL, ATP-citrate lyase; ACSS1, acyl-CoA synthetase short-chain
family, member 1; ACSS2, acetyl-CoA synthetase short-chain family, member 1; BHB, β-hydroxybutyrate; BHB-CoA, β-hydroxybutyryl-CoA;
LCFA, long-chain fatty acid; Mal-CoA, malonyl-CoA; OAD, organic aciduria or acidemia; TCA, tricarboxylic acid cycle
Source: With modifications from: Sabari67
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MMA, and PA have been proposed.20,87 Standard long-
term management for these OADs is based on conserva-
tive management including low lysine diet with precursor-
free, arginine-fortified amino acid supplements, and carni-
tine supplementation in GA1 patients, and low protein
diet with or without precursor-free amino acid supple-
ments, hydroxocobalamin (in responsive MMA patients),
carnitine supplementation, and antibiotically mediated
reduction of intestinal propionate-producing microbiota in
MMA/PA patients. For all OADs, emergency treatment is
recommended to maintain anabolism during potentially
harmful situations and to reduce the production and
enhance the detoxification of toxic metabolites.
Recommended metabolic therapy for MMA and PA
patients does not reliably protect against recurrent meta-
bolic decompensations and the manifestation of long-
term complications.11,12 Furthermore, iatrogenic pre-
scription of dietary treatment may result in chronic
changes of plasma amino acids and other nutrients, pos-
sibly affecting growth and interfering with important cel-
lular mechanisms such as autophagy.88 In contrast,
adherence to recommended therapy markedly reduces
the frequency of striatal damage in screened individuals
with GA1,89-93 while therapeutic deviation increases the
risk of dystonia and untimely death.15,94 But careful eval-
uation of the long-term follow-up of GA1 patients, how-
ever, identified (a) an age-dependent CKD which did not
seem to be impacted by recommended therapy,15 (b) an
increased risk of cerebral accumulation of glutarate and
progressive neuroaxonal compromise in high excretor-
type GA1 patients,85 and (c) the manifestation of malig-
nant brain tumors in three patients with poor adherence
to or late start of therapy.27 Although recommended ther-
apy might be beneficial for the majority of pediatric GA1
patients, as it is for many MMA and PA patients, recent
observations raise the question about whether it reliably
protects against long-term complications in adolescents
and adults. Novel therapeutic strategies aiming to reduce
the cerebral lysine oxidation are currently under investi-
gation. One of these strategies, that is, pharmacologic
inhibition of dehydrogenase E1 and transketolase
domain containing 1 aiming to reduce the production of
glutaryl-CoA, failed to rescue the biochemical and clini-
cal phenotype of Gcdh−/− mice since OGDH provides an
alternative pathway for the generation of glutaryl-CoA.33
While liver transplantation is not thought to be a
therapeutic option for individuals with GA1,87 liver trans-
plantation (PA, MMA), and kidney or combined liver/
kidney transplantation (MMA) can be considered in
MMA and PA patients with frequent metabolic decom-
pensations.20 Nevertheless, experience is still limited and
decisions are highly individualized. While liver or com-
bined liver/kidney transplantation in MMA patients has
become an effective alternative treatment option with
favorable short-term outcome, graft survival, and
survival,95-99 and has led to partial correction of the meta-
bolic derangement, and markedly reduced levels of the
hepatokine and metabolic key regulator FGF21,5,100 this
intervention does not cure the disease but attenuates the
biochemical and clinical phenotype. As a consequence,
conservative metabolic management, although less strict
than before transplantation, is continued in order to
lower the remaining risk of neurologic and renal deterio-
ration.20 Furthermore, the choice of a renal-sparing
immunosuppressive regime is recommended, and poten-
tial neurological complications of certain immunosup-
pressive medications need to be taken into account.101
Compared to MMA, the benefits and risks of liver
transplantation in PA patients are less clear. Some studies
provided evidence that liver transplantation might be
more cost-effective and beneficial than conservative man-
agement102,103 and might halt or even reverse dilated
cardiomyopathy.23,104 This view has been challenged by
the demonstration of high post-transplant mortality, the
development of severe, unusual and unexpected perioper-
ative complications, and worsening of pre-existing kidney
dysfunction.105 Furthermore, the post-transplant lack of
well-known metabolic “red flags” may conceal metabolic
derangements of the “hidden” brain compartment. This
highlights the need to carefully evaluate the individual
risk of perioperative and post-transplant complications
and to take all necessary steps to minimize these risks in
advance.
Innovative therapeutic approaches with promising
results in mouse models include liver-directed recombi-
nant AAV gene delivery (MMA, PA) and systemic mRNA
therapy (MMA).106-109 In analogy to liver transplantation
and animal studies, this novel approach will not cure the
OAD patient but will likely produce an attenuated phe-
notype. Although this approach spares patients from the
risks of organ transplantation and immunosuppressive
therapy, long-term safety and efficacy of these therapies
need further attention. For example, it was demonstrated
that the AAV vector dose, enhancer/promotor selection,
and the timing of gene delivery are critical factors that
determine the risk of developing hepatocellular carci-
noma after AAV gene delivery to the liver.110 Further-
more, both approaches will or are likely to result in a
transient improvement of hepatic enzyme activity. For
mRNA therapy, repetitive applications similar to the fre-
quency of enzyme replacement therapies would be
required to prevent metabolic deterioration.108 In anal-
ogy, liver-directed gene delivery, although being much
more sustained than mRNA therapy, will unlikely result
in life-long rescue of hepatic enzyme deficiency if trans-
gene DNA copies mostly persist as nonintegrated
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episomes and hence are not be transferred to sister cells.
Finally, repetitive applications might be challenging (if
possible at all) with regard to immunologically driven
adverse events and health expenditures.
6 | OUTLOOK: BUILDING
BRIDGES
Recent studies have started to bridge the knowledge gap
between the primary defect of OADs and late onset dis-
ease complications, which develop in the absence of
acute metabolic decompensations. Two new pathophysio-
logical mechanisms thought to sustain and aggravate
metabolite-driven mitochondrial dysfunction and meta-
bolic maladaptation in OADs described are: (a) unbal-
anced autophagy, resulting in impaired quality control of
organelles and thus facilitating organelle aging, and
(b) metabolite-driven short-chain lysine acylation, modu-
lating enzyme function and gene expression. These
mechanisms are complementary to previously described
mechanisms induced by accumulating acyl-CoAs and
carbonic acids, synergizing in impaired mitochondrial
energy metabolism. Exploitation of these mechanisms
might identify selective drug targets in the future that are
suitable to prevent disease progression. At present, organ
(liver, kidney) transplantation in MMA and PA patients
experiences a revival but requires careful pretransplant
evaluation and optimal post-transplant follow-up by a
multiprofessional team including a metabolic specialist
to ensure a favorable long-term outcome. Organ trans-
plantation, similar to a systemic and liver-directed AAV-
mediated mRNA therapy, does not cure the disease,
whereas liver-directed therapies may result in a better
long-term outcome than conservative metabolic manage-
ment. The next years will be substantially determined by
the translation of novel mechanistic findings to targeted
therapies, clinical trials on innovative therapies, the iden-
tification of predictive biomarkers such as FGF21 to iden-
tify high risk patients and to monitor therapies, and the
development of evidence-based and severity-adjusted
algorithms for therapy stratification. These coordinated
efforts are inevitable to fulfill the promise of safe and
effective therapies for individuals with OADs.
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